Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: August 29, 2024
Event: Entry into securities purchase agreements for a public registered offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Structure:
- 1,377,990 shares of Common Stock and accompanying Common Warrants at $3.00 per unit.
- 1,022,010 Pre-Funded Warrants and accompanying Common Warrants at $2.999 per unit.
- Expected Net Proceeds: Approximately $6.3 million (after deducting placement agent fees and offering expenses).
- Placement Agent Fees: Approximately $0.3 million cash commission plus $60,000 in reimbursed expenses.
- Insider Participation: Directors and executive officers purchased an aggregate of 211,000 shares of Common Stock and accompanying Common Warrants.
- Warrant Terms:
- Common Warrants: Exercise price $3.00; Expiration September 3, 2029.
- Pre-Funded Warrants: Exercise price $0.001; No expiration until fully exercised.
- Beneficial Ownership Limitation: 4.99% (electable up to 9.99% with notice).
Material Changes and Unusual Items
This filing reports a significant capital raise event rather than operational performance changes. The transaction involves the issuance of new equity and warrants, which will increase the company's share count and dilute existing shareholders. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the period, as it is a current report on a specific transaction.
Guidance, Outlook, and Risks
- Closing Date: The Company expects to close the Registered Offering on September 3, 2024.
- Regulatory Status: The offering is made pursuant to a Registration Statement on Form S-1 (No. 333-281448) declared effective on August 29, 2024.
- Risks/Contingencies: The transaction is subject to customary conditions to closing. The exercise of warrants is subject to beneficial ownership limitations to prevent holders from exceeding 4.99% (or 9.99%) of outstanding shares without prior notice.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received on or after September 3, 2024.
- Confirm the updated total share count and dilution impact following the issuance of 1,377,990 common shares and the pre-closing exercise of 988,333 shares.
- Review the Placement Agency Agreement (Exhibit 1.1) for any additional contingent fees or obligations.
- Monitor the exercise activity of the Pre-Funded Warrants and Common Warrants over the next five years.